Vor Biopharma Inc.
Close on Oct 19, 2026
- Market cap
- $979.65M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2025 Ended Dec 31, 2025 | Jan 12, 2026 | During market hours | – | – | – |
Press releases
Announcements Vor Biopharma filed with the SEC
First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN)
Regulation FD disclosure · EX-99.1 to Form 8-K
First regulatory approval for Sjögren’s disease (SjD)
Regulation FD disclosure · EX-99.2 to Form 8-K
Vor Bio Announces $75 Million Private Placement with TCGX
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Global Science. One Purpose. 44th Annual J.P. Morgan Healthcare Conference January 2026
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Vor Bio Announces $150 Million Private Placement
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Global Science. One Purpose. 48-week Phase 3 Clinical Trial Data from China for Telitacicept in Primary Sjögren’s Disease October 28, 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Global Science. One Purpose. Corporate
Regulation FD disclosure · EX-99.1 to Form 8-K
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset
Material agreement · Agreement terminated · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Vor Bio Announces $175 Million Private Placement
Material agreement · Agreement terminated · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
Exit or restructuring costs · Executive or director change · Other events · EX-99.1 to Form 8-K
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Vor Bio Announces $55.6 Million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Disclaimer This presentation (the “Presentation”) contains
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Vor Bio Appoints Seasoned Healthcare Institutional Investor,
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
New Clinical Data Validates Vor Bios Approach of Using Shielded Transplants to Deliver Targeted
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
September 2024 Ambition: Curing Blood
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D.,
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
January 2024 Ambition: Curing blood
Other events · EX-99.1 to Form 8-K
Multiple Clinical and Preclinical Presentations at ASH 2023
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Successful Primary Engraftment of Trem-cel in First Five AML
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
First AML Patient Transplanted with Vor Bio’s Trem-cel
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Vor Bio Prices Underwritten Offering of Common Stock and Concurrent
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
First AML Patient Successfully Transplanted with Vor Bio’s
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
VBP101 Clinical Update December 7, 2022
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K